Innovative Pharmaceutical Biotech Limited (HK:0399)
:0399
Top Page
Innovative Pharmaceutical Biotech
(0399)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$0.14
▲(52.22% Upside)
Action:ReiteratedDate:04/02/26
The score is driven primarily by very weak financial performance (sharp revenue decline, severe 2025 loss, ongoing cash burn, and negative equity with high debt). Technical indicators add a modestly negative tilt due to bearish momentum and a weak long-term trend, while valuation offers limited support because earnings are negative and no dividend data is available.
Positive Factors
Improving cash burn trajectory
Reported improvement in cash burn in 2024–2025 versus earlier years indicates management has begun to reduce negative cash flow. If sustained, this structural improvement lowers short-term external funding needs, lengthens runway, and increases the chance of stabilizing operations over the next several months.
Negative Factors
Negative equity and high leverage
Negative equity combined with total debt around the high hundreds of millions creates a structural solvency concern. This severely limits access to conventional financing, raises default or covenant risk, and constrains long-term strategic options, undermining durability absent recapitalization.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash burn trajectory
Reported improvement in cash burn in 2024–2025 versus earlier years indicates management has begun to reduce negative cash flow. If sustained, this structural improvement lowers short-term external funding needs, lengthens runway, and increases the chance of stabilizing operations over the next several months.
Read all positive factors
Innovative Pharmaceutical Biotech (0399) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$399.07M
Dividend YieldN/A
Average Volume (3M)17.09M
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees20
SectorConsumer Cyclical
Sector Strength84
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.06
Shares Outstanding3,167,207,000
10 Day Avg. Volume17,323,689
30 Day Avg. Volume17,085,593
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)143.85
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Innovative Pharmaceutical Biotech Business Overview & Revenue Model
Company Description
Innovative Pharmaceutical Biotech Limited, an investment holding company, engages in the trading of beauty equipment and products in the People's Republic of China and Hong Kong. The company operates in two segments, Trading of Beauty Products, an...
How the Company Makes Money
null...
Innovative Pharmaceutical Biotech Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.27M | 2.09M | 6.59M | 8.07M | 11.14M | 15.19M |
| Gross Profit | 328.00K | 188.00K | 840.00K | 858.00K | 1.05M | 1.41M |
| EBITDA | -15.72M | -310.25M | 317.75M | -18.82M | 228.51M | -18.81M |
| Net Income | -563.85M | -345.94M | 103.40M | -245.70M | 296.54M | -395.75M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 1.09B | 1.38B | 1.38B | 1.39B | 1.40B |
| Cash, Cash Equivalents and Short-Term Investments | 18.07M | 3.70M | 3.08M | 1.33M | 4.08M | 8.99M |
| Total Debt | 1.09B | 1.00B | 1.01B | 1.19B | 941.84M | 991.48M |
| Total Liabilities | 1.19B | 1.06B | 1.06B | 1.24B | 999.73M | 1.04B |
| Stockholders Equity | -783.77M | -681.19M | -611.51M | -795.07M | -549.37M | -595.35M |
Cash Flow | ||||||
| Free Cash Flow | 2.52M | -10.55M | -8.28M | -17.64M | -12.34M | -25.01M |
| Operating Cash Flow | 2.52M | -10.55M | -8.28M | -17.64M | -12.34M | -25.01M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -1.00K | 13.00K |
| Financing Cash Flow | 15.15M | 11.19M | 10.32M | 14.92M | 7.30M | 10.57M |
Innovative Pharmaceutical Biotech Technical Analysis
Negative
0.09
Price Trends
0.14
Negative
0.13
Positive
0.26
Negative
Market Momentum
>-0.01
Positive
44.65
Neutral
28.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0399, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.14, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.65 is Neutral, neither overbought nor oversold. The STOCH value of 28.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0399.
Innovative Pharmaceutical Biotech Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$29.97B | 16.77 | 19.93% | 1.84% | 36.70% | 22.26% | |
64 Neutral | HK$3.09B | 12.04 | 6.65% | 5.90% | 9.72% | -10.15% | |
62 Neutral | HK$712.86M | 6.41 | 4.03% | ― | -0.92% | -71.88% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
48 Neutral | HK$981.03M | 92.72 | -12.38% | ― | 39.29% | -71.82% | |
42 Neutral | HK$399.07M | -1.59 | 76.98% | ― | ― | ― |
* Consumer Cyclical Sector Average
HK:0399
Innovative Pharmaceutical Biotech
0.13
-0.03
-17.65%
HK:0157
Natural Beauty Bio-Technology
0.49
<0.01
1.03%
HK:6601
Cheerwin Group Limited
2.32
0.47
25.34%
HK:9886
Dingdang Health Technology Group Ltd.
0.94
0.60
176.47%
HK:2367
Giant Biogene Holding Co. Ltd.
28.34
-31.19
-52.39%
HK:3332
Nanjing Sinolife United Co., Ltd. Class H
0.44
0.00
0.00%
Innovative Pharmaceutical Biotech Corporate Events
Starcoin Advances Bond Restructuring and Funding Plans After Audit Disclaimer
Apr 1, 2026
Starcoin Group Limited has issued an update on efforts to address a prior audit disclaimer of opinion related to its ability to continue as a going concern, outlining progress on bond restructuring, capital raising, and cost controls. The company ...
Starcoin Group Plans Debt-Equity Deal to Cut Liabilities and Add Strategic Investor
Mar 29, 2026
Starcoin Group Limited has signed a memorandum of understanding with Hong Kong-incorporated Marvel Nice Limited for a possible share subscription, following Marvel Nice’s intended acquisition of HK$715 million in convertible bonds previously...
Starcoin Group Signs Strategic Biotech Cooperation MOU With Huamei Haibo
Mar 25, 2026
Starcoin Group Limited has signed a memorandum of understanding with Chongqing-based Huamei Haibo Biotechnology to pursue strategic cooperation spanning equity investment, asset restructuring, Web3.0 healthcare, joint business development, financi...
Starcoin Secures Exclusive Rights to Tokenize Brazilian Gold Mine Assets
Mar 17, 2026
Starcoin Group Limited has entered into an exclusive management agreement via its subsidiary Starcoin Hong Kong Limited with Brazil-based Nhandu Parkent Mineracao and U.S.-incorporated Goldcoin Global Asset Management to tokenize real-world assets...
Starcoin Expands De-SPAC Talks With Newbridge and Conflux to Bolster Blockchain Push
Mar 11, 2026
Starcoin Group Limited has signed a new memorandum of understanding with NASDAQ-listed Newbridge Acquisition Limited and Conflux Foundation to explore a potential de-SPAC transaction involving the group, Conflux and their respective assets or busi...
Starcoin Group Explores NASDAQ De-SPAC Deal With Newbridge Acquisition
Feb 27, 2026
Starcoin Group Limited has signed a memorandum of understanding with Newbridge Acquisition Limited, a NASDAQ-listed special purpose acquisition company, to explore a potential de-SPAC transaction involving the group and its assets or businesses. T...
Starcoin Extends Convertible Bond Deadline and Delays Key Shareholder Circular
Feb 27, 2026
Starcoin Group Limited has agreed with Extrawell Pharmaceutical Holdings Limited to extend the long stop date for fulfilling conditions under the fourth deed of amendment relating to its outstanding convertible bonds from 31 March 2026 to 30 June ...
Starcoin Partners with China Digital Finance on Gold‑Backed Tokenization Push
Feb 13, 2026
Starcoin Group Limited has signed a strategic cooperation framework agreement with China International Digital Finance Group Limited to develop a gold‑backed real‑world asset tokenization project. Under the arrangement, China Digital F...
Starcoin Group Seeks Review of HKEX Ruling on Insufficient Operations
Feb 10, 2026
Starcoin Group Limited has disclosed that the Hong Kong stock exchange has determined the company failed to maintain a sufficient level of operations as required under listing rules, a finding previously upheld by the Listing Committee. The group,...
Starcoin Group Shares to Remain Suspended After HKEX Cites Insufficient Operations and Asset Support
Feb 1, 2026
Starcoin Group Limited has been notified by the Hong Kong Stock Exchange’s Listing Committee that it failed to maintain a sufficient level of operations and assets of adequate value to justify its continued listing, leading to a decision to ...
Starcoin Group Shifts Principal Hong Kong Office to Central
Jan 19, 2026
Starcoin Group Limited has announced a change to its principal place of business and contact details in Hong Kong, effective 19 January 2026. The company has relocated its main Hong Kong office to the 21st Floor of the Henley Building at 5 Queen&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.